Streetbeat News

Revenues

AUVI

GOOS

NRBO

NeuroBo Pharmaceuticals received FDA clearance for a Phase 1 clinical trial of DA-1726 for obesity treatment, causing NRBO stock to surge 103%. Applied UV projects potential revenues of $250M-$300M over 3-6 years from a new project, boosting AUVI shares by 28%. Canada Goose reported Q3 2024 adjusted EPS of C$1.37, meeting expectations, but sales of C$609.90M fell short of the C$620.05M estimate, leading to a 12% increase in GOOS shares.

Portfolio Pulse from ryanfaloona@benzinga.com

February 01, 2024 | 1:36 pm

BTCUSD

ETHUSD

Cryptocurrencies like Bitcoin, Ethereum, and Dogecoin fell after the Fed left rates unchanged, signaling a temporary setback. Meanwhile, a new ETF allows investment in major tech stocks, and Binance faces a lawsuit for allegedly aiding terrorists. In the US, market sentiment declined following the Fed's decision, impacting stocks and the Dow. Globally, tensions with Iran and China's cyber activities raise concerns. Economic indicators suggest a looming recession, while in tech, Apple's new products and partnerships draw attention. The electric vehicle sector sees advancements and legal challenges for Tesla.

Portfolio Pulse from Akanksha Bakshi

February 01, 2024 | 1:22 pm

BABA

NVDA

SOXL

Nvidia Corp (NASDAQ:NVDA) stock is up amid pre-orders for its new AI chip, the H20, for the Chinese market, competing with Huawei. Despite being less powerful than other Nvidia chips and Huawei's Ascend 910B, the H20 is priced between $12,000 and $15,000. Nvidia aims to maintain its presence in China, facing domestic competition and U.S. sanctions. Reports suggest Chinese cloud companies like Alibaba (NYSE:BABA) may reduce orders for high-end AI chips from Nvidia by 50%-60% within five years. Nvidia's stock gained 194% last year, with an 8% exposure to Direxion Daily Semiconductor Bull 3x Shares (NYSE:SOXL).

Portfolio Pulse from Anusuya Lahiri

February 01, 2024 | 1:19 pm

BLBX

Evtec Aluminium, a target for acquisition by Blackboxstocks (BLBX), has secured a $67M supply contract from Jaguar Land Rover. This contract enhances Evtec's current order book to $847 million, with the parts supplied to be utilized in Jaguar's new electric vehicles set for a 2025 release.

Portfolio Pulse from Benzinga Newsdesk

February 01, 2024 | 1:11 pm

EDAP

EDAP has completed enrollment for its Phase 3 study of Focal One HIFU therapy for deep infiltrating rectal endometriosis, with 60 patients enrolled in under 9 months. Study results are anticipated in the second half of 2024.

Portfolio Pulse from Benzinga Newsdesk

February 01, 2024 | 1:10 pm

ARVN

Analyst ratings for Arvinas (NASDAQ:ARVN) show varied sentiments, with recent updates indicating an average 12-month price target of $45.83, a significant increase from the previous $36.67. Analysts from firms like Goldman Sachs and Wells Fargo have adjusted their ratings and price targets, reflecting evolving market conditions and Arvinas's performance. Despite the optimistic analyst projections, Arvinas faces challenges such as below-average market capitalization, revenue growth below sector average, and poor profitability indicators like net margin and ROE.

Portfolio Pulse from Benzinga Insights

February 01, 2024 | 1:00 pm

ATI

ATI Inc is on track to achieve over $5 billion in revenue and $1 billion in adjusted EBITDA by 2027, driven by unprecedented demand for commercial jet engines. The company's strategic positioning, capabilities, and team are highlighted as key factors in reaching these targets.

Portfolio Pulse from Benzinga Newsdesk

February 01, 2024 | 12:34 pm

HII

Huntington Ingalls Industries (HII) forecasts FY24 free cash flow of $600-$700M, with shipbuilding revenue expected between $8.8B-$9.1B and operating margin at 7.6%-7.8%. Mission Technologies revenue is projected at $2.7B-$2.75B with an operating margin of 3.0%-3.5% and EBITDA margin of 8.0%-8.5%. Other financial metrics include an operating FAS/CAS adjustment of ($63M), an interest expense of ($90M), a non-operating retirement benefit of $178M, and an effective tax rate of ~21%.

Portfolio Pulse from Benzinga Newsdesk

February 01, 2024 | 12:18 pm

PTON

Peloton projects its FY24 revenue to be between $2.675 billion and $2.75 billion, which is slightly below the estimated $2.748 billion.

Portfolio Pulse from Benzinga Newsdesk

February 01, 2024 | 12:18 pm

SRDX

Surmodics has updated its FY24 sales expectations to $117M-$121M, including SurVeil DCB license fee revenue, and $113M-$117M excluding it. This is a slight adjustment from the prior guidance of $116M-$121M and $112M-$117M, respectively. The new forecast is closely aligned with the consensus estimate of $119.26M.

Portfolio Pulse from Benzinga Newsdesk

February 01, 2024 | 12:13 pm